JPMorgan Chase & Co. Raises Stake in Corcept Therapeutics Incorporated $CORT

JPMorgan Chase & Co. boosted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 223.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 849,864 shares of the biotechnology company’s stock after purchasing an additional 587,053 shares during the quarter. JPMorgan Chase & Co.’s holdings in Corcept Therapeutics were worth $70,632,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in CORT. AQR Capital Management LLC increased its position in shares of Corcept Therapeutics by 546.9% during the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after buying an additional 1,274,215 shares during the period. Norges Bank purchased a new stake in shares of Corcept Therapeutics in the second quarter worth about $72,048,000. Epoch Investment Partners Inc. bought a new position in shares of Corcept Therapeutics in the second quarter valued at approximately $56,181,000. UBS Group AG boosted its position in shares of Corcept Therapeutics by 413.8% in the third quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock valued at $45,705,000 after acquiring an additional 442,898 shares during the period. Finally, Pacer Advisors Inc. grew its stake in Corcept Therapeutics by 6,796.7% during the third quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after acquiring an additional 384,896 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Trading Down 0.6%

Shares of Corcept Therapeutics stock opened at $33.30 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $117.33. The firm has a market cap of $3.54 billion, a PE ratio of 40.61 and a beta of 0.29. The company has a 50 day simple moving average of $37.57 and a two-hundred day simple moving average of $62.37.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same period in the previous year, the company earned $0.26 EPS. Corcept Therapeutics’s quarterly revenue was up 11.1% on a year-over-year basis. Analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CORT has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target on the stock. HC Wainwright lowered their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Finally, Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $77.17.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Lead‑plaintiff deadline: multiple firms remind investors that April 21, 2026 is the deadline to move for lead plaintiff in the pending securities class action — an immediate procedural date that could determine litigation leadership and the pace of the case. Robbins LLP Notice
• Negative Sentiment: Allegations of disclosure failures and regulatory/patent setbacks: Hagens Berman and others say the lawsuit stems from an alleged concealment of repeated FDA warnings about insufficient data and a federal court patent loss — claims that, if proven, could drive material damage awards or settlements and prolonged expense. Hagens Berman Alert
• Negative Sentiment: Multiple law firms soliciting clients: At least a dozen plaintiff firms (Robbins, Levi & Korsinsky, Rosen, Pomerantz, Kahn Swick & Foti, Glancy, Bronstein, Schall, Bernstein, Gross, et al.) have issued investor alerts and filings covering the Oct. 31, 2024–Dec. 30, 2025 class period — increasing the likelihood of a contested, high‑profile suit and amplification of reputational and financial risk. Kahn Swick & Foti / GlobeNewswire

Insider Buying and Selling

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the sale, the insider owned 1,235 shares in the company, valued at $50,474.45. This trade represents a 94.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 48,233 shares of company stock valued at $1,817,306 over the last quarter. 20.80% of the stock is owned by corporate insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.